Two-Year Efficacy of Ranibizumab Plus Laser-Induced Chorioretinal Anastomosis vs Ranibizumab Monotherapy for Central Retinal Vein Occlusion A Randomized Clinical Trial

Grants

Funding Acknowledgements

The ranibizumab used in this study was supplied by Novartis (Sydney, New South Wales, Australia). The Centre for Eye Research Australia receives operational infrastructure support from the Victorian government. Drs Sanfilippo and Chen are supported by National Health and Medical Research Council Early Career Fellowships.